Ophthalmic Drugs: bright eyes
Incidence rate of China’s eye upward trend is expected each year will add one million eye patients, and our
Ophthalmic drugs was less than 2 per-capita annual, huge contrast between the supply and demand indicates that —
? ophthalmic market capacity increases with superior enterprises are growing rapidly,
According to insiders, the past, most of ophthalmic drugs is that enterprises are for rich product lines and production subsidiary
Products. At present, the ophthalmic drug market is still in the stage of development, the country is about more than 6,000 pharmaceutical companies, from the
Ophthalmic drug production enterprise things are currently only 130 or so. Not because of market demand, the market return is low, add
The lack of effective drugs, so the field of ophthalmic drugs have long been overlooked.
In recent years, ophthalmic drugs have been spun off from the facial features among drug as a single drug class sections
Do not treat in eye hospitals and eye disease treatment drug manufacturers have also increased. Up to now, through the
GMP-certified ophthalmic drug production enterprises (workshops) has five, with a professional sales force lack of ophthalmic drugs
10, and most of them joint ventures.
It is understood that in 2003 the National Eye drugs more than 1.5 billion total sales
Yuan, there has been a true industry leader and a number of strong brands, such as the Chia Tai Freda last year’s sales of more than
500 million yuan; Le Dun, Yun Shu, Yun-Jie 3 billion in brand sales were off; in prescription and non-prescription drug market,
The rise of a number of outstanding enterprises. With the improvement in the quality of people’s lives and health care, increasing awareness, eye
Health care and the prevention and treatment of eye disease has been widespread attention, ophthalmic drugs is absolutely the rapid growth of market capacity,
Ophthalmic drug prices are also rising, but in China the proportion of the total pharmaceutical market has never been more than 1%.
There are two reasons: First, eye diseases illness rate is not high, the market capacity is relatively small; second eye drug prices
Relatively low, but a larger input.
? technology brand is the trump card high-low-end each a car
According to China National Pharmaceutical Society of Medicine Economic Information Net (CPN) network in 16 cities to procure medicines at the amount of the hospital
Statistics show that last year’s second quarter, Beijing network hospital from 105 ophthalmic drug manufacturers buy drugs, their
Joint-venture pharmaceutical companies in the domestic and 88 foreign pharmaceutical companies 17. Although the number of foreign pharmaceutical companies is less than the domestic pharmaceutical companies, but the country
Ophthalmic drug production enterprises with foreign professional company with a number of patented products, prices higher than domestic medicine, so
Hospital ophthalmic pharmaceutical companies buying foreign varieties is higher than the total amount of domestic and joint-venture pharmaceutical factory. Beijing Eye Hospital, Chang
The doctor told reporters that the domestic and foreign brands compared to ophthalmic drugs still have gaps. Some difficult cases such as
Ocular fundus, age-related macular degeneration have not yet curative effect of drugs.
Professor Chen Youxin said, foreign investment, joint ventures, mainly in three aspects of the product advantage: product prices and profits; product technical content; marketing concepts and methods. In terms of price and profit, foreign investment, joint ventures, is taking the high-end product line, product quality and internal and external packaging are first-class average, they invested in each eye-drops on the packaging and quality control costs are often higher than the domestic one normal eye syrup selling price is high. On the technical side, with the present more sophisticated artificial tears, for example, there were only Rui Zhu Qianjiang pharmaceutical eye drops and Nanjing Liye Pharmaceutical Co., Ltd. for the production if the two species, while the foreign pharmaceutical companies for each eye has a their artificial tear products, such as Novartis Pharmaceuticals Nuopei gel is a fifth-generation artificial tears. In the marketing concepts and tools, the “three capital” enterprises a more forward-thinking,
Practices more flexible. Such as Chia Tai Freda’s Run clean drops dew, did not apply for drug approval number, but by approval of the declaration of disinfection products, and directly positioned in the “visual fatigue.” Chia Tai Freda plus in each of the varieties
Huge investment in advertising costs (more than 10 million yuan per year), not only does not because the products are not drugs and become
Disadvantage, but because of less advertising restrictions, rapid cast of its ophthalmic products of the brand, sales far more than
The other eye drops.
Medical equipment store in Wangfujing, gold like the big pharmacy, a dollar court Xibahe stores, Golden Elephant Xibahe
Shops, pharmacies, etc. visit Qinghe Chen National Tsing Hua University found that Chinese-made ophthalmic drugs go, mostly low-cost routes, the price
In a few cents or a majority of two dollars; while foreign-funded enterprise products, such as anti-fatigue eye drops as, domestically
8ml bottle priced at 1.8 yuan, while the joint venture 15ml bottle price of 19.5, if compared with the same volume,
Both the ratio of 1 to 5. Chang-Tai Hong in Beijing, pharmacy, its manager Zhu Qiang told reporters that a single foreign-funded enterprise products
Speaking from packaging made in China opened with a grade, as the most sensitive organs of the body – eyes, consumption
Are generally would not mind spending a few dollars to spend money. However, the domestic ophthalmic drugs, especially some old brand, but also have a more
A stable consumer group. Beijing Wan Hui medicine under the Pharmaceutical Sales Shuangji a Mr. Feng Xing said they were from 19
58 years, began production of erythromycin, in the Beijing market with annual sales of several hundred thousand dollars, but in other regional markets are
Very few sales.
? optimized combination of the general trend of the regular Army and more capable
As market competition intensifies, the domestic production of ophthalmic drug companies have gradually to professional development, a few
Large ophthalmic drug manufacturer is taking shape. Medical information from the U.S. Rand Consulting Co., Ltd. for the top 10
The ophthalmic drug varieties of analysis, we can see: ophthalmology drug market concentration is increasing. From the variety of view, living
In the top 10 drugs the number and amount of the purchase exceeds the total market respectively 75% and 60% of the copies of
Amount.
As competition intensifies and market segments, ophthalmic products, whether in products or manufacturing enterprises has been
After gradually developed a unique system in the field of ophthalmic drug has formed several teams to promote professionalism
Strength, but strength of these teams are still expanding in the field of ophthalmic drug trend toward the formation of monopolies. Currently
Ophthalmic drugs in the domestic market leader in the production of enterprises Chia Tai Freda, Hubei Qianjiang, Shenyang
Xing Qi, Hangzhou Tian Mu Shan, Allergan, Jiangxi Pharmaceutical companies value the next, most of which have become specialized
The ophthalmic drug manufacturers.
I am a professional writer from China Manufacturers, which contains a great deal of information about piezoelectric transducer , power massager, welcome to visit!
Processing your request, Please wait....
